ExtriCARE USA Launches Innovative Medical Device Company, Offering Negative Pressure Wound Therapy Solutions

ExtriCARE USA  a national medical device company specializing in the distribution of negative pressure wound therapy (NPWT), officially announces its company launch and new user-centric website.

ExtriCARE USA, led by President Peter Mason, who has over eight years of industry experience, is fostering the future of healthcare with wound care technologies that improve patient outcomes, help clinicians with efficiency and reduce overall costs. NPWT is a modern resource still in its infancy stage. With a tailored and hands-on approach, the ExtriCARE USA team is working diligently to amplify its potential.

“I have a driving passion to develop reliable NPWT products for our network of dealers, which in turn helps patients live a better-quality life,” said Mason. “I am excited to continue building strong partnerships with dealers nationwide, allowing us to support patients and clinicians alike while reaching new heights of growth together.”

To coincide with the company’s launch, ExtriCARE USA has built a new website designed with the user in mind. The website has in-depth information on the ExtriCARE product line, the leadership team and press page with the company’s latest insights.

“With over a decade of experience in wound care, I am fortunate and proud to be a part of such a dynamic and forward-thinking team,” said Gary Schear, Vice President of Sales. “Our patient-first mentality is a driving force, and we hope to continue being a trustworthy lifeline for our providers so that they can be the lifeline for their patients.”

The ExtriCARE USA leadership team, comprised of Peter Mason, Gary Schear and Tony Cheung (Director of Operations), is committed to the future of NPWT. In partnership with Alleva Medical, the company is introducing a new product line that will transform traditional NPWT. The products are designed to be versatile, featuring state-of-the-art technology and optimized software. ExtriCARE USA and Alleva Medical will bring these portable, powerful and adaptive solutions to the market soon.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”